Joerg Lippert
Overview
Explore the profile of Joerg Lippert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
204
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Eissing T, Goulooze S, van den Berg P, van Noort M, Ruppert M, Snelder N, et al.
Diabetes Obes Metab
. 2023 Dec;
26(3):924-936.
PMID: 38037539
Aims: To perform dose-exposure-response analyses to determine the effects of finerenone doses. Materials And Methods: Two randomized, double-blind, placebo-controlled phase 3 trials enrolling 13 026 randomized participants with type 2...
2.
Yassen A, Coboeken K, Bailly S, Burghaus R, Buskova J, Dogas Z, et al.
ERJ Open Res
. 2022 Nov;
8(4).
PMID: 36329798
Introduction: The European Sleep Apnea Database was used to identify distinguishable obstructive sleep apnoea (OSA) phenotypes and to investigate the clinical outcome during positive airway pressure (PAP) treatment. Method: Prospective...
3.
Goulooze S, Heerspink H, van Noort M, Snelder N, Brinker M, Lippert J, et al.
Clin Pharmacokinet
. 2022 May;
61(7):1013-1025.
PMID: 35508594
Background And Objective: Finerenone reduces the risk of kidney failure in patients with chronic kidney disease and type 2 diabetes. Changes in the urine albumin-to-creatinine ratio (UACR) and estimated glomerular...
4.
Miller T, Kaiser A, Schmelter T, Lippert J, Davis J
Semin Fetal Neonatal Med
. 2022 Apr;
27(4):101331.
PMID: 35469712
Persistent pulmonary hypertension of the newborn (PPHN) is a complication of term birth, characterized by persistent hypoxemia secondary to failure of normal postnatal reduction in pulmonary vascular resistance, with potential...
5.
Schneider A, Schneider C, Schneider K, Baier V, Schaper S, Diedrich C, et al.
Liver Int
. 2022 Jan;
42(3):640-650.
PMID: 35007409
Background & Aims: Decompensation is a hallmark of disease progression in cirrhotic patients. Early detection of a phase transition from compensated cirrhosis to decompensation would enable targeted therapeutic interventions potentially...
6.
Goulooze S, Snelder N, Seelmann A, Horvat-Broecker A, Brinker M, Joseph A, et al.
Clin Pharmacokinet
. 2021 Nov;
61(3):451-462.
PMID: 34786651
Background: Finerenone is a nonsteroidal selective mineralocorticoid receptor antagonist (MRA) that demonstrated efficacy in delaying the progression of chronic kidney disease (CKD) and reducing cardiovascular events in patients with CKD...
7.
van den Berg P, Ruppert M, Mesic E, Snelder N, Seelmann A, Heinig R, et al.
Clin Pharmacokinet
. 2021 Nov;
61(3):439-450.
PMID: 34773606
Background: Finerenone is a nonsteroidal selective mineralocorticoid receptor antagonist that recently demonstrated efficacy in delaying chronic kidney disease progression and reducing cardiovascular events in patients with chronic kidney disease and...
8.
Marx G, Bickenbach J, Fritsch S, Kunze J, Maassen O, Deffge S, et al.
BMJ Open
. 2021 Sep;
11(4):e045589.
PMID: 34550901
Introduction: The acute respiratory distress syndrome (ARDS) is a highly relevant entity in critical care with mortality rates of 40%. Despite extensive scientific efforts, outcome-relevant therapeutic measures are still insufficiently...
9.
Krauss M, Hofmann U, Schafmayer C, Igel S, Schlender J, Mueller C, et al.
NPJ Syst Biol Appl
. 2017 Jun;
3:11.
PMID: 28649438
Early indication of late-stage failure of novel candidate drugs could be facilitated by continuous integration, assessment, and transfer of knowledge acquired along pharmaceutical development programs. We here present a translational...
10.
Niederalt C, Wendl T, Kuepfer L, Claassen K, Loosen R, Willmann S, et al.
Front Physiol
. 2013 Jan;
3:494.
PMID: 23355822
A physiologically based kidney model was developed to analyze the renal excretion and kidney exposure of hydrophilic agents, in particular contrast media, in rats. In order to study the influence...